Rocuronium 2 mg/kg: Onset and Duration
At a dose of 2 mg/kg, rocuronium is not a standard dosing regimen and lacks specific pharmacodynamic data in the provided evidence. However, based on the dose-response relationship established in FDA labeling and clinical studies, this supramaximal dose (approximately 6-7 times the ED95) would be expected to produce an extremely rapid onset of less than 1 minute and a prolonged clinical duration exceeding 60-90 minutes.
Understanding the Dose-Response Relationship
The FDA-approved rocuronium labeling provides clear pharmacodynamic parameters for standard doses 1:
Standard Dosing Parameters:
- 0.6 mg/kg (2 × ED95): Onset to 80% block in median 1.0 minute (range 0.4-6 minutes), with maximum blockade in less than 3 minutes and clinical duration of 31 minutes (15-85 minutes) 1
- 0.9-1.2 mg/kg (3-4 × ED95): Can be administered safely without adverse cardiovascular effects 1
Extrapolating to 2 mg/kg
While 2 mg/kg is not specifically studied in the provided evidence, the dose-response curves demonstrate:
Expected Onset:
- Onset time decreases logarithmically with increasing dose
- At 1.2 mg/kg, onset approaches that of succinylcholine
- At 2 mg/kg, onset would likely be 30-60 seconds to maximum blockade
Expected Duration:
- Clinical duration increases linearly with dose
- The 1.2 mg/kg dose referenced in guidelines for "very deep blockade" requiring 8 mg/kg sugammadex for immediate reversal 2
- At 2 mg/kg, clinical duration (to 25% recovery) would likely exceed 60-90 minutes
Clinical Context and Reversal Implications
This supramaximal dose creates a "very deep blockade" scenario. According to 2020 French guidelines on muscle relaxants 2:
Reversal Requirements:
- Very deep blockade (3-15 minutes after high doses of 1.0-1.2 mg/kg) requires sugammadex 8 mg/kg for reversal in 3-5 minutes
- At 2 mg/kg rocuronium, you would need sugammadex 8 mg/kg for immediate reversal
- Neostigmine would be completely ineffective until substantial spontaneous recovery occurs
Important Caveats
Why This Dose Is Not Standard:
- No clinical indication for such high dosing in routine practice
- Prolonged paralysis without proportional clinical benefit
- Increased risk of residual paralysis
- Significantly increased cost (both drug and reversal agent)
- Recent evidence suggests doses >1.2 mg/kg improve first-attempt intubation success 3, 4, but 2 mg/kg exceeds even these recommendations
Patient-Specific Factors:
- Elderly patients and those with renal/hepatic impairment would have even more prolonged effects 2
- Females demonstrate greater sensitivity to rocuronium 5
- Sickle cell patients show paradoxically longer onset and shorter duration 6
Monitoring is Essential:
- Quantitative neuromuscular monitoring (TOF) is mandatory at any dose
- Post-tetanic count (PTC) monitoring needed for very deep blockade
- Continued monitoring after reversal to detect recurarization 2